Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced a strategic collaboration with Bayer to evaluate ...
A new preclinical study in the journal Signal Transduction and Targeted Therapy describes a very promising therapeutic ...
Recently published Metastatic Castration-resistant Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, metastatic castration-resistant ...
A noninvasive DNA blood test can identify patients with metastatic castration-resistant prostate cancer (mCRPC) who are most ...
Bayer and Kairos Pharma will study Kairos’ lead antibody, ENV-105 (carotuximab), in combination with Bayer’s Xofigo ...
Novartis AG ended Q2 on a high note as oncology offset Entresto weakness; 2026 guidance reaffirmed. Read why NVS stock is ...
A noninvasive DNA blood test can identify metastatic castration-resistant prostate cancer (mCRPC) patients who are most ...
In a new research report, scientists at Johns Hopkins University School of Medicine and Johns Hopkins Kimmel Cancer Center ...
In this long-term follow-up to the phase 2 ARTO trial, researchers analyzed survival outcomes in patients with CRPC treated with metastasis-directed therapy.
A noninvasive DNA blood test can identify metastatic castration-resistant prostate cancer (mCRPC) patients who are most likely to benefit ...
AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced that updated clinical results from the Phase 1b TheraPb trial ...
An enhanced telehealth model demonstrates feasibility and high clinician and patient acceptability for prostate cancer management.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results